Jpmorgan Chase & CO Alkermes Plc. Transaction History

Jpmorgan Chase & CO

  • $1.51 Trillion
  • Q3 2025

A detailed history of Jpmorgan Chase & CO transactions in Alkermes Plc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 3,928,170 shares of ALKS stock, worth $114 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,928,170
Previous 3,928,170 -0.0%
Holding current value
$114 Million
Previous $118 Million -0.0%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 07, 2025
SELL
$26.13 - $30.46 $34.1 Million - $39.8 Million
-1,306,825 Reduced 24.96%
3,928,170 $118 Million
Q1 2025

May 12, 2025
BUY
$28.08 - $36.0 $122 Million - $156 Million
4,345,523 Added 488.55%
5,234,995 $173 Million
Q4 2024

Feb 12, 2025
BUY
$25.7 - $31.46 $13.6 Million - $16.7 Million
529,962 Added 147.41%
889,472 $25.6 Million
Q3 2024

Dec 26, 2024
SELL
$23.01 - $28.55 $1.07 Million - $1.33 Million
-46,577 Reduced 11.47%
359,510 $10.1 Million
Q3 2024

Nov 08, 2024
SELL
$23.01 - $28.55 $1.07 Million - $1.33 Million
-46,577 Reduced 11.47%
359,510 $10.1 Million
Q2 2024

Dec 26, 2024
BUY
$23.21 - $27.24 $1.08 Million - $1.27 Million
46,577 Added 12.96%
406,087 $9.79 Million
Q2 2024

Aug 12, 2024
SELL
$23.21 - $27.24 $3.75 Million - $4.4 Million
-161,605 Reduced 28.47%
406,087 $9.79 Million
Q1 2024

Dec 26, 2024
BUY
$26.4 - $32.56 $5.5 Million - $6.78 Million
208,182 Added 57.91%
567,692 $15.4 Million
Q1 2024

May 10, 2024
SELL
$26.4 - $32.56 $701,131 - $864,728
-26,558 Reduced 4.47%
567,692 $15.4 Million
Q4 2023

Dec 26, 2024
BUY
$23.37 - $28.68 $5.49 Million - $6.73 Million
234,740 Added 65.29%
594,250 $16.5 Million
Q4 2023

Feb 12, 2024
BUY
$23.37 - $28.68 $5.45 Million - $6.68 Million
232,993 Added 64.5%
594,250 $16.5 Million
Q3 2023

Nov 14, 2023
BUY
$27.17 - $31.97 $362,447 - $426,479
13,340 Added 3.83%
361,257 $10.1 Million
Q2 2023

Aug 11, 2023
BUY
$28.34 - $33.63 $751,180 - $891,396
26,506 Added 8.25%
347,917 $10.9 Million
Q1 2023

May 18, 2023
BUY
$25.31 - $29.02 $5.49 Million - $6.29 Million
216,740 Added 207.07%
321,411 $9.06 Million
Q1 2023

May 11, 2023
SELL
$25.31 - $29.02 $4.3 Million - $4.93 Million
-169,797 Reduced 61.86%
104,671 $2.95 Million
Q4 2022

Feb 13, 2023
SELL
$21.94 - $26.24 $106,738 - $127,657
-4,865 Reduced 1.74%
274,468 $7.17 Million
Q3 2022

Nov 14, 2022
BUY
$22.0 - $31.87 $91,278 - $132,228
4,149 Added 1.51%
279,333 $6.24 Million
Q2 2022

Aug 11, 2022
BUY
$26.4 - $30.54 $2.88 Million - $3.33 Million
109,135 Added 65.72%
275,184 $8.2 Million
Q1 2022

May 11, 2022
BUY
$23.07 - $27.99 $3.83 Million - $4.65 Million
166,049 New
166,049 $4.37 Million

Others Institutions Holding ALKS

# of Institutions
401
Shares Held
176M
Call Options Held
901K
Put Options Held
400K
View Full List

About Alkermes plc.

ALKS Quotes by TradingView
  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.77B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email